Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 27

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 27
---
 Typically, the findings of this study are presented to the Compensation Committee by the compensation consultant in conjunction with the Compensation Committee’s annual review of our executive compensation program.

Because the biotechnology sector is dynamic, the comparator group used by the Compensation Committee to assess the competitive positioning of the compensation of our executive officers is updated annually to ensure that peer companies continue to meet the established criteria. For purposes of its review of our executive compensation program in fiscal 2024, the Compensation Committee directed Compensia to update the compensation peer group reflecting the competitive market for executive talent based on the following criteria:

• Publicly-held, U.S. biotechnology companies;

• Companies with lead assets that are in mid to late clinical stage or early commercialization stage;

• Companies with market capitalizations between 0.25x to 4.0x our market capitalization at the time of the peer selection; and

• Companies with between 92 to 1,311 employees.

The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies. Consideration was also given to the frequency or infrequency with which a company was identified as a peer with other peer companies.

For fiscal 2024, the compensation peer group was generated in the first quarter of fiscal 2024 and consisted of the following companies:

| ACADIA Pharmaceuticals, Inc. |     | Insmed                   |
| Amicus Therapeutics          |     | Intellia Therapeutics    |
| Apellis Pharmaceuticals      |     | Ionis Pharmaceuticals    |
| Arcus Biosciences            |     | Ironwood Pharmaceuticals |
| BioCryst Pharmaceuticals     |     | Mirati Therapeutcis      |
| Blueprint Medicines          |     | Madrigal Pharmaceuticals |
| BridgeBio Pharma             |     | REGENXBIO                |

| CRISPR Therapeutics AG    |     | Sarepta Therapeutics       |
| Deciphera Pharmaceuticals |     | Ultragenyx Pharmaceuticals |
| Denali Therapeutics       |     | Vir Biotechnology          |
| Halozyme Therapeutics     |     |                            |

BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Ironwood Pharmaceuticals, and Madrigal Pharmaceuticals were added to the compensation peer group and Chemo Centryx, FibroGen, Novavax, amd Reata Pharmaceuticals were removed from the compensation peer group due to changes in our business complexity, employee base and market capitalization, as well as mergers, changes to business complexity, employee base and market capital